tag:blogger.com,1999:blog-28450497.post3355559126764689421..comments2009-11-13T13:00:14.791-05:00Adam J. Fein, Ph.D.http://www.blogger.com/profile/12217252282643255442noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-28450497.post-85666915686546734972009-11-13T13:00:14.791-05:002009-11-13T13:00:14.791-05:00Adam-I want to second the comment above about insight. I had not even considered the possibility of PBMs outside the US because of price controls. But now you have me rethinking the forecasts from brand companies.<br /><br />How do you think up this stuff? I&#39;m impressed. <br /><br />And do you ever sleep?Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-28450497.post-65688097635744757042009-11-13T10:54:31.150-05:002009-11-13T10:54:31.150-05:00Insightful as ever. Have you looked at globalization opportunity for leading drug retailers in the US? Japan, India and China apart from Europe are markets that these players could look at. Any thoughtsAnonymousnoreply@blogger.comtag:blogger.com,1999:blog-28450497.post-45386047716706045392009-11-13T09:00:32.434-05:002009-11-13T09:00:32.434-05:00Adam, very interesting. How do you think about this considering the idea that many other countries utilize a single payer system which negotiates or establishes prices for branded drugs, decreasing the need for PBM-type services? That leads to lower levels of generic penetration, but aren&#39;t those countries already getting branded drugs at a steep discount to US prices? Would love your thoughts.Georgenoreply@blogger.com